Macrophages are major upstream regulators of the inflammatory response to implanted biomaterials. Sequential functions of distinct macrophage phenotypes are essential to the normal tissue repair process, which ideally results in vascularization and integration of implants. Improper timing of M1 or M2 macrophage activation results in dysfunctional healing in the form of chronic inflammation or fibrous encapsulation of the implant. Thus, biphasic drug delivery systems that modulate macrophage behavior are an appealing approach to promoting implant integration. In this review, we describe the timing and roles of macrophage phenotypes in healing, then highlight current drug delivery systems designed to sequentially modulate macrophage behavior.
Sequential Drug Delivery to Modulate Macrophage Behavior and Enhance Implant Integration
Creators
Erin M. O’Brien - Biomaterials and Regenerative Medicine Laboratory, School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, PA, United States
Gregory E. Risser - Drexel University
Kara L. Spiller - Drexel University
Publication Details
Advanced drug delivery reviews, v 149-150
Publisher
Elsevier
Resource Type
Journal article
Language
English
Academic Unit
School of Biomedical Engineering, Science, and Health Systems
Web of Science ID
WOS:000503094100006
Scopus ID
2-s2.0-85066091849
Other Identifier
991019169164304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: